Coronavirus-World’s largest vaccine maker is set to produce 40 million units of vaccine

The Serum Institute of India is all set for mass-producing a coronavirus vaccine without confirming if it is effective.

The Serum Institute of India is the world’s largest vaccine maker, according to the international news source. The drug has been developed by the University Oxford. The Serum Institute makes 1.5 billion vaccine doses a year.

The University Oxford expects that human trials hAdOx1 nCoV-19 will be conducted in September.
the vaccine was given to the first two women on Thursday in oxford. Around 1,100 people in the UK will take part in the trial.

The group said, “We may get enough data in a couple of months to see if the vaccine works, but  if transmission levels drop, this could take up to six months,”

The group expects it might produce one million doses by September.

CEO of Serum Institute of India Adar Poonawalla reported to the international news agency that he would not wait for so long.

He also said that 5 million units of the vaccine would be produced in a month, for six months, to meet the demands.

He said, “We are not waiting for the trials to get over in September in the UK, and then start production here. The decision — at our own risk and cost — has been solely taken to get a jump-start on manufacturing, to have enough doses available, if the clinical trials prove successful,”

“We aim to manufacture four to five million doses per month for the first six months, following which, we might scale up to 10 million doses per month, based on the success of trials. We are looking to build it up to 20-40 million doses by September-October.”

“We are planning to make the vaccine available at an affordable price of around 1,000 rupees ($13) in India,” he also said that the prices of the vaccine may vary in countries.

Professor Sarah Gilbert, who is leading the Oxford’s efforts in making the vaccine, said on 11th April that September was the assumed month in which it can work.

She said, “I think there’s a high chance that it will work based on other things that we have done with this type of vaccine,”